also soon be in the market with map3 cellular allogeneic bone
graft, which incorporates Athersys' MAPC stem cells, under 361
as well. This opens the question about other cell therapy ... also be in the market shortly with map3 cellular allogeneic bone graft, which
incorporates Athersys' MAPC stem cells. We believe that there are several other companies/products
positioned ideally ... regulation is written, they will meet the first
criterion. On the other hand, Athersys' MAPC, Mesoblast's mesenchymal precursor cells (MPC), or
Pluristem's Placental eXpanded (PLX) cells will